Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

332
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
332
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

291
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
291
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

213
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Proteomics01:33

Proteomics

7.9K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study.

European journal of neurology·2026
Same author

Association of Triglyceride-Glucose Index, Triglyceride/HDL Cholesterol Ratio and Metabolic Score for Insulin Resistance With Asymptomatic Organ Damage in Previously Untreated Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same author

Reproducibility of Ambulatory Blood Pressure Variability in Untreated Hypertensive Patients.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same author

Peptidomic Profiling Reveals Extracellular Matrix Remodeling Signatures Discriminative of Multiple Myeloma.

Proteomics·2026
Same author

Blood pressure determinants of target organ damage among adults with white coat hypertension with a focus on nocturnal hypertension and blood pressure dipping.

Journal of human hypertension·2026
Same author

Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Sep 9, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

604

Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study.

Oraianthi Fiste1, Martina Samiotaki2, Efstathios Manios1

  • 1Department of Clinical Therapeutics & Laboratory, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.

Proteomics. Clinical Applications
|August 29, 2025
PubMed
Summary

Ribociclib, a breast cancer drug, can cause cardiovascular toxicities (CVTs) in less than 10% of patients. Proteomics identified proteins that may predict CVT risk, aiding personalized prevention strategies for breast cancer patients.

Keywords:
CDK4/6 inhibitorsbreast cancercardio‐oncologyproteomicsribociclib

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.5K

Related Experiment Videos

Last Updated: Sep 9, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

604
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.5K

Area of Science:

  • Oncology
  • Cardiology
  • Proteomics

Background:

  • Cyclin-dependent kinase 4/6 inhibitors, including ribociclib, are vital for HR+, HER2- metastatic breast cancer.
  • Cardiovascular toxicities (CVTs) associated with ribociclib require further characterization.
  • Understanding the molecular mechanisms of ribociclib-induced CVTs is crucial for patient management.

Purpose of the Study:

  • To assess the incidence and spectrum of treatment-related CVTs in patients receiving ribociclib.
  • To identify differentially expressed proteins in patients experiencing CVTs using DIA LC-MS/MS.
  • To explore potential predictive biomarkers for ribociclib-associated cardiovascular events.

Main Methods:

  • Prospective, single-center study enrolling adult patients treated with ribociclib.
  • Clinical data collection for CVT incidence, type, and timing.
  • Serum proteomics analysis using data-independent acquisition liquid chromatography-tandem mass spectrometry (DIA LC-MS/MS) in cases versus controls.

Main Results:

  • Five cases (8.06%) of CVT occurred among 62 participants after a median follow-up of 27.2 months.
  • Observed CVTs included QTc prolongation, transient ischemic attack, deep vein thrombosis, syncope, and pericardial effusion.
  • Proteomics identified 144 differentially expressed proteins, with pathways like immune response and metabolism significantly affected.

Conclusions:

  • Ribociclib-induced CVTs are not rare and present with diverse clinical manifestations beyond QTc prolongation.
  • Proteomic analysis revealed potential predictive biomarkers for identifying patients at high risk of CVT.
  • Further validation in larger cohorts is needed to support individualized cardiovascular prevention strategies for breast cancer patients on ribociclib.